Amgen Company Leadership
| AMGN Stock | USD 296.85 1.39 0.47% |
About 58% of Amgen's corporate insiders are selling. The analysis of the overall insider sentiment regarding Amgen Inc suggests that many insiders are alarmed. Amgen employs about 28 K people. The company is managed by 22 executives with a total tenure of roughly 51 years, averaging almost 2.0 years of service per executive, having 1272.73 employees per reported executive.
| Robert Bradway Chairman Chairman, CEO and President Chairman of Executive Committee and Member of Equity Award Committee |
| Murdo Gordon President Executive Vice President of Global Commercial Operations |
Insider Sentiment 42
Mostly Selling
Selling | Buying |
Latest Trades
| 2025-06-05 | Rachna Khosla | Disposed 1500 @ 289.68 | View | ||
| 2025-05-14 | Marjorie Taylor Greene | Acquired @ 262.28 | |||
| 2025-05-05 | Marjorie Taylor Greene | Acquired @ 280.06 | |||
| 2025-04-16 | Jared Moskowitz | Acquired @ 282.64 | |||
| 2025-04-15 | Tommy Tuberville | Disposed @ 295.3 | |||
| 2025-04-11 | Jefferson Shreve | Acquired @ 285.98 | |||
| 2025-04-09 | Ro Khanna | Acquired @ 291.09 | |||
| 2025-04-08 | Robert Bresnahan, Jr. | Disposed @ 280.26 | |||
| 2025-02-24 | Jefferson Shreve | Acquired @ 309.72 | |||
| 2025-02-21 | David M Reese | Disposed 25225 @ 304.44 | View | ||
| 2025-02-19 | David M Reese | Disposed 8711 @ 293.22 | View | ||
| 2025-02-11 | Murdo Gordon | Disposed 8771 @ 294.79 | View | ||
| 2025-02-07 | Jonathan P Graham | Disposed 25045 @ 293.12 | View | ||
| 2025-02-05 | Nancy A Grygiel | Disposed 1589 @ 304.47 | View |
Monitoring Amgen's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Acquired vs Disposed
Filed vs Not Filed
Insider sentiment refers to the collective sentiment or feeling of Amgen's insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Amgen Inc. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Amgen's stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. Amgen Management Team Effectiveness
The company has return on total asset (ROA) of 0.0704 % which means that it generated a profit of $0.0704 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 1.0567 %, meaning that it created $1.0567 on every $100 dollars invested by stockholders. Amgen's management efficiency ratios could be used to measure how well Amgen manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Amgen's Total Assets are very stable compared to the past year. As of the 5th of July 2025, Non Current Assets Total is likely to grow to about 65.9 B, while Total Current Assets are likely to drop about 15.6 B.As of the 5th of July 2025, Common Stock Shares Outstanding is likely to grow to about 740.9 M, while Net Income Applicable To Common Shares is likely to drop about 5 B.
Amgen Workforce Comparison
Amgen Inc is number one stock in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 67,649. Amgen totals roughly 28,000 in number of employees claiming about 41% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.17 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.29 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.29. Amgen Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Amgen insiders, such as employees or executives, is commonly permitted as long as it does not rely on Amgen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Amgen insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Miller Derek over six months ago Disposition of tradable shares by Miller Derek of Amgen at 311.29 subject to Rule 16b-3 | ||
Matthew Busch over a year ago Disposition of 1753 shares by Matthew Busch of Amgen at 230.92 subject to Rule 16b-3 | ||
Matthew Busch over a year ago Disposition of 2508 shares by Matthew Busch of Amgen at 235.97 subject to Rule 16b-3 | ||
Matthew Busch over a year ago Disposition of 2508 shares by Matthew Busch of Amgen at 235.97 subject to Rule 16b-3 | ||
Matthew Busch over a year ago Disposition of 2508 shares by Matthew Busch of Amgen at 235.97 subject to Rule 16b-3 | ||
Matthew Busch over a year ago Disposition of 2508 shares by Matthew Busch of Amgen at 235.97 subject to Rule 16b-3 | ||
Matthew Busch over a year ago Disposition of 2508 shares by Matthew Busch of Amgen at 235.97 subject to Rule 16b-3 | ||
Williams R Sanders over a year ago Acquisition by Williams R Sanders of 846 shares of Amgen subject to Rule 16b-3 |
Amgen Notable Stakeholders
An Amgen stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Amgen often face trade-offs trying to please all of them. Amgen's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Amgen's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Robert Bradway | Chairman, CEO and President Chairman of Executive Committee and Member of Equity Award Committee | Profile | |
| Murdo Gordon | Executive Vice President of Global Commercial Operations | Profile | |
| Esteban Santos | Executive Vice President Operations | Profile | |
| Jonathan Graham | Senior Vice President General Counsel, Secretary | Profile | |
| Peter Griffith | Executive CFO | Profile | |
| Jonathan JD | General VP | Profile | |
| Linda Louie | VP Officer | Profile | |
| Mr MD | Senior Officer | Profile | |
| James MD | Executive Development | Profile | |
| Nancy Grygiel | Senior Officer | Profile | |
| Ian Thompson | Senior Operations | Profile | |
| Scott Skellenger | Senior Officer | Profile | |
| Darryl MD | Senior Medical | Profile | |
| Derek Miller | Senior Resources | Profile | |
| Justin Claeys | Vice Relations | Profile | |
| Matthew Busch | Chief Finance | Profile | |
| Kave Niksefat | Senior Access | Profile | |
| Jerry Murry | Senior Development | Profile | |
| Mike Zahigian | Senior Officer | Profile | |
| Alan Russell | Vice Biologics | Profile | |
| David MD | Executive Officer | Profile | |
| Arvind Sood | IR Contact Officer | Profile |
About Amgen Management Performance
The success or failure of an entity such as Amgen Inc often depends on how effective the management is. Amgen management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Amgen management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Amgen management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California. Amgen operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 24200 people.
Amgen Workforce Analysis
Traditionally, organizations such as Amgen use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Amgen within its industry.Amgen Manpower Efficiency
Return on Amgen Manpower
| Revenue Per Employee | 1.2M | |
| Revenue Per Executive | 1.5B | |
| Net Income Per Employee | 146.1K | |
| Net Income Per Executive | 185.9M | |
| Working Capital Per Employee | 211.8K | |
| Working Capital Per Executive | 269.6M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amgen. If investors know Amgen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amgen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.19) | Dividend Share 9.13 | Earnings Share 10.98 | Revenue Per Share 63.49 | Quarterly Revenue Growth 0.094 |
The market value of Amgen Inc is measured differently than its book value, which is the value of Amgen that is recorded on the company's balance sheet. Investors also form their own opinion of Amgen's value that differs from its market value or its book value, called intrinsic value, which is Amgen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amgen's market value can be influenced by many factors that don't directly affect Amgen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amgen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Amgen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amgen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.